NVIDIA is further embedding itself in the biopharma industry. Its artificial intelligence tools are now more accessible, integrated and it is taking a strategic collaborative approach with competitors like Google to bolster AI-driven startups that ultimately use its tools.
NVIDIA has increased its presence across the life sciences industry. The company recently added a suite of over 24 “microservices” to its offerings, hoping its tools will be more widely adopted across the industry.
The services include AI models and workflows for drug discovery, including generative chemistry, protein structure prediction and molecule-target docking prediction,...
Create an account to read this article
Already a subscriber?
IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.
Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.
The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.
The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.
